Your browser doesn't support javascript.
loading
Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
Wang, Sue-Jane; Fotenos, Anthony; Masters, Shane C; Marzella, Louis.
Afiliación
  • Wang SJ; Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
  • Fotenos A; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
  • Masters SC; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
  • Marzella L; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
Theranostics ; 12(7): 3079-3083, 2022.
Article en En | MEDLINE | ID: mdl-35547778
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Medicina de Precisión / Nanomedicina Teranóstica Tipo de estudio: Prevalence_studies / Risk_factors_studies Idioma: En Revista: Theranostics Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Medicina de Precisión / Nanomedicina Teranóstica Tipo de estudio: Prevalence_studies / Risk_factors_studies Idioma: En Revista: Theranostics Año: 2022 Tipo del documento: Article